NCT00667342 arm group 68c6d2c97005e7eccfed5add01750bfe [clinicaltrials_resource:NCT00667342/arm-group/68c6d2c97005e7eccfed5add01750bfe]
Methotrexate [clinicaltrials_resource:4e547eff981137da06134ca5808b643c]Doxorubicin [clinicaltrials_resource:6a8adb62348e1864e9650e6152c566aa]Cisplatin [clinicaltrials_resource:9874a4234f5594cc82868395a7343063]Bevacizumab [clinicaltrials_resource:c4202e745f68a1fdd802342460106e4c]Surgery [clinicaltrials_resource:e7cf0833399bc7ded2ada79408b35af0]clinicaltrials:NCT00667342
arm group [clinicaltrials_vocabulary:arm-group]
NCT00667342 arm group 68c6d2c97005e7eccfed5add01750bfe [clinicaltrials_resource:NCT00667342/arm-group/68c6d2c97005e7eccfed5add01750bfe]
Bio2RDF identifier
NCT00667342/arm-group/68c6d2c97005e7eccfed5add01750bfe
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... c6d2c97005e7eccfed5add01750bfe
description [clinicaltrials_vocabulary:description]
Participants with localized re ...... doxorubicin, or methotrexate.
identifier
clinicaltrials_resource:NCT00667342/arm-group/68c6d2c97005e7eccfed5add01750bfe
title
NCT00667342 arm group 68c6d2c97005e7eccfed5add01750bfe
@en
type
label
NCT00667342 arm group 68c6d2c9 ...... 6d2c97005e7eccfed5add01750bfe]
@en